



14 May 2026

Proteome Sciences plc
(“Proteome Sciences” or the “Company”)

Result of Annual General Meeting (AGM)

The directors of Proteome Sciences are pleased to announce that at the Company's AGM, held at 12.00 noon today, all resolutions were duly passed.

For information, the proxy votes received in relation to the resolutions were as follows:

RESOLUTION MATTER	VOTES FOR	VOTES AGAINST	VOTES DISCRETIONARY	VOTES WITHHELD	VOTES TOTAL
1. To receive the report of the Directors and the audited Financial Statements of the Company for the year ended 31 December 2025.	147,914,675	2,800,402	539	71,282	150,786,898
2. To receive and approve the Remuneration Report, excluding the remuneration policy.	146,482,388	4,232,689	539	71,282	150,786,898
3. To re-appoint Christopher Pearce as a Director of the Company.	147,740,986	2,890,589	0	155,323	150,786,898
4. To re-appoint Richard Dennis as a Director of the Company.	147,704,238	2,947,337	0	135,323	150,786,898
5. To re-appoint Ian Pike as a Director of the Company.	147,724,238	2,927,337	0	135,323	150,786,898
6. To re-appoint Ursula Ney as a Director of the Company.	147,741,085	2,910,490	0	135,323	150,786,898
7. To re-appoint Martin Diggle as a Director of the Company.	147,564,238	3,067,337	0	155,323	150,786,898
8. To re-appoint Cooper Parry Group Limited as auditors of the Company and to authorise the Directors to determine the remuneration of the auditors.	147,796,267	2,890,439	0	100,192	150,786,898
9. To authorise the Directors to exercise all or any of the powers of the Company to allot equity securities up to an aggregate nominal amount of £1,168,966.13.	147,727,873	2,978,396	0	80,629	150,786,898
10. To empower the Directors to disapply statutory pre-emption rights up to a maximum aggregate nominal amount of £701,449.82.	146,526,989	4,179,957	0	79,952	150,786,898

Proteome Sciences plc
 Christopher Pearce, Executive Chairman

Tel: +44 (0) 20 7043 2116

Dr. Ian Pike, Chief Scientific Officer

Richard Dennis, Chief Commercial Officer

SP Angel Corporate Finance LLP (Nominated Adviser & Broker)

David Hignell/Richard Morrison/Josh Ray (Corporate Finance) Tel: +44 (0) 20 3470 0470
Vadim Alexandre (Corporate Broking)

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, with analysis using a range of depletion strategies in combination with TMTcalibrator™ providing access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Chemoproteomics using Solvent Shift reveals the selectivity that drugs have to binding one or more proteins in the sample proteome. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

Further information on the Company can be found on its website at: <https://www.proteomics.com/>

The Company's LEI is 213800Q62ICXANKU2986.

This announcement should be read in its entirety. In particular, the information in the "Important Notices" section of the announcement should be read and understood.